Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC trimmed its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 21.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 65,351 shares of the company's stock after selling 17,851 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Takeda Pharmaceutical were worth $865,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Blair William & Co. IL increased its holdings in Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after purchasing an additional 913 shares during the last quarter. Sage Rhino Capital LLC increased its holdings in Takeda Pharmaceutical by 14.9% in the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after purchasing an additional 1,538 shares during the last quarter. Aaron Wealth Advisors LLC increased its holdings in Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock valued at $331,000 after purchasing an additional 1,670 shares during the last quarter. OLD Mission Capital LLC increased its holdings in Takeda Pharmaceutical by 13.7% in the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after purchasing an additional 1,687 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Takeda Pharmaceutical by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after purchasing an additional 1,770 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded down $0.20 on Monday, reaching $14.17. The company's stock had a trading volume of 5,381,637 shares, compared to its average volume of 1,903,078. The stock's 50-day moving average is $14.87 and its two-hundred day moving average is $14.00. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The stock has a market capitalization of $45.07 billion, a P/E ratio of 35.41, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The firm had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.